Presented By: Maureen Shogan, MN, RNC
May 2011

Watch the Neonatal Abstinence Syndrome webinar to hear about exciting, new data which affect neonatal outcomes when using prenatal buprenorphine compared to the more familiar drug, methadone. Successful strategies are shared with the goal to maintain reliability and avoid common pitfalls when using the neonatal abstinence scoring tool.

Objectives:

• Differentiate variations in neonatal withdrawal from prenatal exposure to oxycodone and hydrocodone versus buprenorphine (Subutex^®) and methadone.
• Discuss reliable, consistent, and objective nursing assessment of neonatal abstinence syndrome utilizing definitions for scorers.
• Describe variations in pharmacologic interventions for the newborn experiencing withdrawal from opiates.